Exploring Novel Approaches to Diabetic Retinopathy Pipeline and Clinical Trials (2023) | Companies – Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular , Bayer, and Others

Exploring Novel Approaches to Diabetic Retinopathy Pipeline and Clinical Trials (2023) | Companies - Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular , Bayer, and Others

(Albany) DelveInsight's "Diabetic Retinopathy Pipeline Insight 2023" report offers extensive knowledge on more than 50+ companies and 50+ pipeline drugs within the landscape of Diabetic Retinopathy research. The Diabetic Retinopathy Pipeline report provides detailed profiles of the Diabetic Retinopathy pipeline drugs, encompassing both Diabetic Retinopathy clinical trials and nonclinical stage products. Additionally, it assesses the therapeutics based on product type, stage, route of administration, and molecule type. Furthermore, the report sheds light on inactive pipeline products in this field.

 

In the Diabetic Retinopathy Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Diabetic Retinopathy clinical trials studies, Diabetic Retinopathy NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

To explore more information on the latest breakthroughs in the Diabetic Retinopathy Pipeline treatment landscape of the report, click here @ Diabetic Retinopathy Pipeline Outlook

 

Key Takeaways from the Diabetic Retinopathy Pipeline Report

  • DelveInsight's Diabetic Retinopathy Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
  • The leading Diabetic Retinopathy Companies are working in the market include Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others
  • Promising Diabetic Retinopathy Pipeline therapies in the various stages of development include KSI-301, Brolucizumab, RGX 314, OTT-166, OTX-TKI, Octreotide Acetate in Microspheres 20 mg, Entelon Tab. 50mg, Intravitreal aflibercept injection [IAI], Sham, ruboxistaurin, candesartan, Lucentis, Vitis vinifera extract, and others
  • KSI-301 is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in the secretion of vascular endothelial growth factor (VEGF), which causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes of patients with diabetic retinopathy. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGF agents.
  • RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. The company is currently enrolling patients in ALTITUDE, a Phase II trial for the treatment of diabetic retinopathy using suprachoroidal delivery of RGX-314.
  • OTT-166 is a novel small molecule selective integrin inhibitor that OcuTerra has purpose-engineered to have the required physiochemical characteristics to be able to reach the retina from eye drop application. Phase 1b clinical trials of OTT-166 eye drops have demonstrated safety, tolerability, and clear clinical evidence of biological activity. OcuTerra is currently studying the safety, efficacy, and optimal dosing regimen of OTT166 through the Phase II DR: EAM (Diabetic Retinopathy: Early Active Management) study in patients with moderately-severe to severe non-proliferative and mild proliferative diabetic retinopathy.

 

Diabetic Retinopathy Overview

Diabetic retinopathy (DR) is a microvascular disorder that occurs due to the long-term effects of diabetes mellitus. Diabetic retinopathy may lead to vision-threatening damage to the retina, eventually leading to blindness. It is the most common cause of severe vision loss in adults of working age groups in the western world. Early detection and timely intervention are the keys to avoiding blindness due to diabetic retinopathy.

 

For further information, refer to the detailed Diabetic Retinopathy Unmet Needs, Diabetic Retinopathy Market Drivers, and Diabetic Retinopathy Market Barriers, click here for Diabetic Retinopathy Ongoing Clinical Trial Analysis

 

Diabetic Retinopathy Emerging Drugs Profile

  • KSI-301: Kodiak Sciences
  • Brolucizumab: Novartis
  • RGX 314: Regenxbio Inc.
  • OTT-166: OcuTerra Therapeutics
  • OTX-TKI: Ocular Therapeutix

 

Diabetic Retinopathy Pipeline Therapeutics Assessment

There are approx. 50+ diabetic retinopathy companies which are developing the therapies for Diabetic Retinopathy. The diabetic retinopathy companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. phase III include, Kodiak Sciences.

 

Request a sample and discover the recent advances in Diabetic Retinopathy Ongoing Clinical Trial Analysis and Medications, click here @ Diabetic Retinopathy Treatment Landscape

 

Diabetic Retinopathy Pipeline Segmentation

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Diabetic Retinopathy Therapeutics Market include-

Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others

 

Dive deep into rich insights for drugs for Diabetic Retinopathy Pipeline, click here @ Diabetic Retinopathy Unmet Needs and Analyst Views

 

Scope of the Diabetic Retinopathy Pipeline Report

  • Coverage- Global
  • Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
  • Diabetic Retinopathy Pipeline Therapies- KSI-301, Brolucizumab, RGX 314, OTT-166, OTX-TKI, Octreotide Acetate in Microspheres 20 mg, Entelon Tab. 50mg, Intravitreal aflibercept injection [IAI], Sham, ruboxistaurin, candesartan, Lucentis, Vitis vinifera extract, and others
  • Diabetic Retinopathy Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Diabetic Retinopathy Mergers and acquisitions, Diabetic Retinopathy Licensing Activities @ Diabetic Retinopathy Emerging Drugs, and Recent Trends

 

Table of Content

  1. Introduction
  2. Diabetic Retinopathy Executive Summary
  3. Diabetic Retinopathy: Overview
  4. Diabetic Retinopathy Pipeline Therapeutics
  5. Diabetic Retinopathy Therapeutic Assessment
  6. Diabetic Retinopathy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. KSI-301: Kodiak Sciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RGX 314: Regenxbio Inc
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. OTX-TKI: Ocular Therapeutix
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Diabetic Retinopathy Key Companies
  21. Diabetic Retinopathy Key Products
  22. Diabetic Retinopathy- Unmet Needs
  23. Diabetic Retinopathy- Market Drivers and Barriers
  24. Diabetic Retinopathy- Future Perspectives and Conclusion
  25. Diabetic Retinopathy Analyst Views
  26. Diabetic Retinopathy Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.